Alzheimer’s is a disease of aggregation. Neurons in the human brain make a protein called amyloid beta. Such proteins on their own, called monomers of amyloid beta, perform important tasks for neurons. But in the brains of people with Alzheimer’s disease, amyloid beta monomers have abandoned their jobs and joined together. First, they form oligomers — small clumps of up to a dozen proteins — then longer strands and finally large deposits called plaques. For years, scientists believed that the plaques triggered the cognitive impairments characteristic of Alzheimer’s disease. But newer research implicates the smaller aggregates of amyloid beta as the toxic elements of this disease.
Now, a team led by researchers at the University of Washington has developed synthetic peptides that target and inhibit those small, toxic aggregates. As they report in a paper published April 19 in the Proceedings of the National Academy of Sciences, their synthetic peptides — which are designed to fold into a structure known as an alpha sheet — can block amyloid beta aggregation at the early and most toxic stage when oligomers form.
The team showed that the synthetic alpha sheet’s blocking activity reduced amyloid beta-triggered toxicity in human neural cells grown in culture, and inhibited amyloid beta oligomers in two laboratory animal models for Alzheimer’s. These findings add evidence to the growing consensus that amyloid beta oligomers — not plaques — are the toxic agents behind Alzheimer’s disease. The results also indicate that synthetic alpha sheets could form the basis of therapeutics to clear toxic oligomers in people, according to corresponding author Valerie Daggett, a UW professor of bioengineering and faculty member in the UW Molecular Engineering & Sciences Institute.
“This is about targeting a specific structure of amyloid beta formed by the toxic oligomers,” said Daggett. “What we’ve shown here is that we can design and build synthetic alpha sheets with complementary structures to inhibit aggregation and toxicity of amyloid beta, while leaving the biologically active monomers intact.”
Cellular proteins assume many different 3D structures, usually by first folding into certain types of basic shapes. The alpha sheet is a nonstandard protein structure, discovered by Daggett’s group using computational simulations. The research team has previously shown that alpha sheets are associated with aggregation of amyloid beta. These and related findings indicate that, in nature, alpha sheets likely occur in only rare instances when proteins fold incorrectly and interact in ways that disrupt cellular function, leading to so-called “protein misfolding” diseases like Alzheimer’s.
In this new paper, Daggett and her team provide evidence that amyloid beta oligomers form an alpha sheet structure as they aggregate into longer strands and plaques. Critically, the team’s synthetic alpha sheets can actually block this aggregation by specifically binding and neutralizing the toxic oligomers.
Using both novel and conventional spectroscopic techniques, Daggett’s team observed the individual stages of development of amyloid beta clusters, from monomers to six- and 12-protein oligomers all the way up to plaques, in human neural cell lines. The researchers confirmed that the oligomer stages were most toxic to the neurons, which agrees with clinical reports of amyloid beta plaques in the brains of people who don’t have Alzheimer’s.
“Amyloid beta definitely plays a lead role in Alzheimer’s disease, but while historically attention has been on the plaques, more and more research instead indicates that amyloid beta oligomers are the toxic agents that disrupt neurons,” said Daggett.
In addition, the researchers designed and built small, synthetic alpha sheet peptides, each made up of just 23 amino acids, the building blocks of proteins. The synthetic peptides folded into a hairpin-like structure and are not toxic to cells. But the synthetic alpha sheets neutralized the amyloid beta oligomers in human neural cell cultures, inhibiting further aggregation by blocking parts of the oligomers involved in the formation of larger clumps.
The peptides also protected laboratory animals from toxic oligomer damage. In brain tissue samples from mice, the team observed an up to 82% drop in amyloid beta oligomer levels after treatment with a synthetic alpha sheet peptide. Administering a synthetic alpha sheet to living mice triggered a 40% drop in amyloid beta oligomer levels after 24 hours. In the common laboratory worm Caenorhabditis elegans, another model for Alzheimer’s disease, treatment with synthetic alpha sheets delayed the onset of amyloid beta-induced paralysis. In addition, C. elegans worms showed signs of intestinal damage when they were fed bacteria that express amyloid beta. That damage was inhibited when the scientists first treated the bacteria with their synthetic alpha sheets.
Daggett’s team is continuing experiments with synthetic alpha sheets to engineer compounds that are even better at clearing amyloid beta oligomers. For the current study, the researchers also created a novel laboratory assay that uses a synthetic alpha sheet to measure levels of amyloid beta oligomers. They believe this assay could form the basis of a clinical test to detect toxic oligomers in people before the onset of Alzheimer’s symptoms.
“What we’re really after are potential therapeutics against amyloid beta and diagnostic measures to detect toxic oligomers in people,” said Daggett. “Those are the next steps.”
The Latest on: Synthetic peptide
via Google News
The Latest on: Synthetic peptide
- Global Synthetic Peptides Market 2017-2026| Thermo Fisher Scientific, Innovagen AB, Sigma-Aldrich, Sino Biological, Biomatikon March 29, 2020 at 4:53 am
The report involves insightful data on the main sectors of the Global Synthetic Peptides Market. The report has segmented market, by its types and applications. Each segment has analyzed completely on ...
- Global Peptide Synthesis Equipment Market strategy 2020 : By Key Palyers AAPPTec, PTI, PSI,CEM , Biotage, Shimadzon March 27, 2020 at 3:06 pm
The global Peptide Synthesis Equipment Market 2020-2026 report is designed through some uniquely defined primary as well as secondary research methods to represent the industry-oriented data more ...
- Vaccine Combo 'Provocative' as Cervical Cancer Treatmenton March 27, 2020 at 2:22 pm
"Standard-of-care carboplatin and paclitaxel chemotherapy of late cervical cancer depletes suppressive myeloid cells, but not lymphocytes, allowing a robust T cell immune response to timed ...
- Peptide Synthesis Market Research Report By Current & Future Trends, Statistics To 2026on March 26, 2020 at 3:21 am
In accordance with the study held by Acumen Research, the Peptide Synthesis Market size is projected to reach US$ 400 Mn by 2026 with a CAGR of 6.6% throughout the forecast period 2019 to 2026. The ...
- A new algorithm to convert a normal antibody into the corresponding catalytic antibodyon March 25, 2020 at 12:00 pm
On the other four synthetic substrates, S38 did not exhibit any catalytic activity. Therefore, S38 is considered to have a trypsin-like function. Regarding the scissile peptide bond, the T99-Pro95(−) ...
- A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosison March 24, 2020 at 3:18 am
Idiopathic pulmonary fibrosis is associated with increased abundance of Staphylococcus and Streptococcus in the lungs. Here, the authors identify a Staphylococcus nepalensis-derived peptide, named ...
- Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026 | Reports and Dataon March 23, 2020 at 5:33 pm
New York, March 23, 2020 -- The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a.
- Peptide Therapeutics Market Detailed Analysis by Key Players | Incyte, Amgen, Pfizeron March 23, 2020 at 9:21 am
Advance Market Analytics released a new market study on Global Peptide Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed ...
- An expanded library of orthogonal split inteins enables modular multi-peptide assemblieson March 23, 2020 at 3:14 am
Inteins allow the joining of protein segments through scarless ligation. Here the authors assess 34 inteins to establish a library of 15 mutually orthogonal split inteins for in vivo applications, 10 ...
- Paving the way for new peptide-based therapeutics with novel method of phage displayon March 19, 2020 at 3:03 pm
Pérez, who performed the molecular dynamics simulations that enabled the team to understand the selectivity involved for specific peptides. "The beauty of this work, at least in my mind, is that it ...
via Bing News